Wound healing in diabetes
02.02.2010 16:29
GlucoMetrix Pharma GmbH successfully launches the new medical product range BIOSept
Wilhelmine S. had no longer dared to hope for that: the 15 x 18 centimeter wound on the 80-year-old lady's calf had not healed for two years. But now the wound has closed completely within five weeks after multiple dressing changes and a moist wound environment through treatment with BIOSept wound spray, wound rinse and wound gel. GlucoMetrix Pharma GmbH has been receiving positive news like this every day for several weeks.
The reason: BIOSept helps immediately with an open wound and makes the wound germ-free in two days and as a result the wound can heal naturally. In December 2009, the company from Ruhpolding in Upper Bavaria successfully launched onto the market with its four wound healing products, BioSept wound gel, BioSept wound spray, BioSept wound rinse and BioSept mouth rinse. The product had recently been certified by LGA-Intercert according to the EN ISO 13485:2003+AC2007 standard. 98.9 percent of chronic wounds were treated positively or healed during the clinical phase. No side effects were noted.
“We were clear about the intensive effectiveness of the products. “But we were very surprised and pleased that we were able to sell more than 10,000 wound care products on the market in the first week after approval,” says Peter Paul Schikora, Managing Director of GlucoMetrix Pharma. 21 million patients in Germany can be helped with BIOSept wound healing products - up to the relief and complete healing of the wound.
BIOSept is particularly suitable for poorly healing wounds in diabetics, which are described as chronic if they have not healed for four weeks or longer. The BIOSept Wundgel product is also reimbursable for all patients who have it prescribed by their doctor. Since there are no preservatives in BIOSept, BIOSept wound care is also suitable for allergy sufferers. The market launch of a new collagen plaster in various sizes is planned for the middle of the year, which is currently in the official approval process.
This means that GlucoMetrix Pharma GmbH can provide patients, pharmacists and doctors with consistent wound care for poorly healing wounds. GlucoMetrix Pharma GmbH has set itself the goal of sustainably increasing the quality of life of diabetics. An amputation due to diabetic foot syndrome takes place in Germany every 19 minutes. “The number could be reduced by at least a third if diseased feet were discovered in good time and treated accordingly,” says Peter Paul Schikora.
What applies to diabetics is also important to non-diabetics. Any inflammatory germs in the bloodstream can support inflammation in organs or the threatening arteriosclerosis. This is an important aspect of maintaining health, especially for older people, and therefore even non-diabetics can use BIOSept products without hesitation. Diabetes mellitus is a metabolic disease in which the transport and absorption of glucose from the blood into the cells is disturbed and blood sugar is therefore increased. People who suffer from it have to regulate their blood sugar levels with injected insulin.
In Germany, experts estimate the number of diabetics at 7.5 million. According to the International Diabetes Foundation (IDF), the probability of developing diabetes mellitus in the adult population (20 to 79 years of age) was 12 percent in 2010. This prevalence rate is the highest in Europe. According to IDF information, 27,585 deaths among men and 26,994 deaths among women in Germany can be attributed to diabetes each year. Glucometrix AG, the parent of GlucoMetrix Pharma GmbH, focuses on the early detection and control of diabetes mellitus. The focus of research and development is on improving the quality of life of diabetics. To this end, the life science company develops IT-based medical devices as well as highly effective medical products and genetically engineered drugs for the disease “diabetes mellitus”.